Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Adagio Medical Holdings, Inc Common Stock Market Cap
Based on ratings from 0 stock analysts, the Adagio Medical Holdings, Inc Common Stock stock price is expected to decrease by 100% in 12 months. This is calculated by using the average 12-month stock price forecast for Adagio Medical Holdings, Inc Common Stock. The lowest target is $ and the highest is $. Please note analyst price targets are not guaranteed and could be missed completely.
ADGM is a stock in Healthcare which has been forecasted to be worth $ as an average. On the higher end, the forecast price is $ USD by from and on the lower end ADGM is forecasted to be $ by from .
These are the latest 20 analyst ratings of ADGM.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
Data Not Found! | ||||
When did it IPO
2024
Staff Count
87
Country
United States
Sector/Industry
Healthcare/Medical Devices
CEO
Mr. Olav B. Bergheim
Market Cap
$39.0M
In 2023, ADGM generated $300,000 in revenue, which was a increase of 58.73% from the previous year. This can be seen as a signal that ADGM's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 07 Oct 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Adagio Medical Holdings, Inc. (Nasdaq: ADGM) will sponsor and participate in the 19th Annual International Symposium on Ventricular Arrhythmias on October 11-12, 2024, in Brooklyn, NY.
Why It Matters - Adagio Medical's participation in a key symposium highlights its commitment to innovation in cardiac technologies, potentially enhancing its market visibility and attracting investment interest.
Mon, 19 Aug 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Adagio Medical Holdings, Inc. (Nasdaq: ADGM) received CE Mark approval and launched the vCLAS™ catheter and ULTC system for ventricular tachycardia in select European markets.
Why It Matters - Adagio Medical's CE Mark approval and product launch for the vCLAS™ catheter enhances its market position, potentially driving revenue growth and attracting investor interest in the medical technology sector.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
